Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer

Br J Cancer. 1995 May;71(5):1055-60. doi: 10.1038/bjc.1995.203.


The present study compares the prognostic potential of tumour grade and DNA ploidy status in patients with advanced-stage prostatic cancer. Two outcome groups were selected on the basis of time to progression and survival after orchiectomy. A poor-outcome group consisted of 32 therapy-resistant patients who experienced disease progression during the first year after orchiectomy and subsequently death due to prostatic cancer during the following year. A good-outcome group consisted of 27 therapy-responsive patients who showed disease regression and no signs of progression during a 3 year follow-up. The primary tumours were graded twice according to WHO and Gleason classification systems by two pathologists. Final agreement between the pathologists was obtained after a consensus meeting. The analysis revealed no prognostic importance of the two histological classification systems (P = 0.62 and P = 0.70) and disclosed weak inter- and intra-observer reproducibility (kappa < 0.70). DNA ploidy analyses were performed by image cytometry on formalin-fixed, paraffin-embedded samples of the primary tumours. Overall, 48% of the tumours were diploid, 20% tetraploid and 32% anueploid. DNA ploidy status did not discriminate between the two outcome groups (P = 0.46). Histological grade and DNA ploidy showed no prognostic importance in patients with prostatic cancer and skeletal metastases.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor*
  • Bone Neoplasms / secondary
  • DNA, Neoplasm / genetics*
  • Evaluation Studies as Topic
  • Humans
  • Male
  • Middle Aged
  • Observer Variation
  • Ploidies*
  • Prognosis
  • Prostatic Neoplasms / classification
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology*
  • Reproducibility of Results


  • Biomarkers, Tumor
  • DNA, Neoplasm